详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Comparison of Different Biologics for Treating Chronic Rhinosinusitis with Nasal Polyps: A Network Analysis.

4| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, P.R. China [2]Beijing Key Laboratory of Nasal Diseases and Beijing Laboratory of Allergic Diseases, Beijing Institute of Otorhinolaryngology, Beijing, P.R. China [3]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, P.R. China [4]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, P.R. China

出处：

DOI：

ISSN：

摘要：

Several promising clinical trials have demonstrated the effects of type 2 biologics compared with placebos in chronic rhinosinusitis with nasal polyps (CRSwNP). However, there are no head-to-head randomized controlled trials (RCTs) between the biologics.To compare the efficacy and safety of different biologics used for the treatment of CRSwNP.We systematically identified RCTs investigating the effects of biologics for CRSwNP. Primary outcomes were nasal polyp score (NPS), nasal congestion severity, and serious adverse events. Secondary outcomes included the 22-item Sino-Nasal Outcome Test (SNOT-22) score, loss of smell severity, the University of Pennsylvania Smell Identification Test score, and the Lund-Mackay computed tomography score. Bucher indirect treatment comparison (ITC) was used to compare the outcome parameters.Seven RCTs (Bachert 2017, OSTRO, POLYP 1, POLYP 2, SINUS-24, SINUS-52, and SYNAPSE) involving 1913 patients and 4 biologics (benralizumab, dupilumab, mepolizumab, and omalizumab) were included for ITC. Dupilumab presented better effects in decreasing NPS and nasal congestion severity compared with the other 3 biologics at 24 weeks of the treatment and at the end of follow-up (more than 48 weeks). Benralizumab was the least effective in reducing nasal congestion severity and SNOT-22 score at 24 weeks. No significant differences were observed between the effects of the other biologics.Our current findings suggest that dupilumab exhibits the best efficacy and safety for the treatment of CRSwNP.Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区过敏 1 区免疫学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区过敏 1 区免疫学

JCR分区：

出版当年[2020]版：

Q1 ALLERGY Q1 IMMUNOLOGY

最新[2023]版：

Q1 ALLERGY Q1 IMMUNOLOGY

影响因子： 8.2 最新[2023版] 8.3 最新五年平均 8.861 出版当年[2020版] 8.643 出版当年五年平均 7.574 出版前一年[2019版] 11.022 出版后一年[2021版]

第一作者：

第一作者机构： [1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, P.R. China [2]Beijing Key Laboratory of Nasal Diseases and Beijing Laboratory of Allergic Diseases, Beijing Institute of Otorhinolaryngology, Beijing, P.R. China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, P.R. China [2]Beijing Key Laboratory of Nasal Diseases and Beijing Laboratory of Allergic Diseases, Beijing Institute of Otorhinolaryngology, Beijing, P.R. China [3]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, P.R. China [4]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, P.R. China [*1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No. 1, DongJiaoMinXiang, DongCheng District, Beijing 100730, P.R. China. [*2]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No. 1, DongJiaoMinXiang, DongCheng District, Beijing 100730, P.R. China

推荐引用方式(GB/T 7714)：

APA：

MLA：